Sweegen’s Bestevia® Rebaudioside M Approved in Europe
Forging the future with better sugar reduction solutions for food and beverages in the region.
Rancho Santa Margarita, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- Sweegen’s footprint in Europe became stronger after the European Union Commission published its approval of Sweegen’s non-GMO Signature Bestevia Rebaudioside M (Reb M) for use in food and beverages.
The approval of Sweegen’s Signature Bestevia Reb M leads the future of wellness in food and drink in Europe. Brands in Europe now have access to the best-tasting highly sought-after stevia sweetener. The availability broadens the toolkit for sugar alternatives to reimagine food and drink, opening new doors for creating healthy products for consumers.
“Sweegen’s Signature Bestevia Reb M approval is a celebration of good health and wellness for product developers and consumers alike,” said Luca Giannone, SVP of Sales. “This is just one of our many milestones in Europe to transform products for having a positive and lasting impact on our ever-evolving health.”
Consumers are increasingly aware of the need to reduce sugar in their diets for better health. Yet, when they are making decisions for purchasing food and beverages, consumers will ultimately select the brand with the best taste. Therefore, tackling the toughest sugar reduction challenges is a priority for brands as taste is the reason for repeat purchases.
The soft drinks industry in Europe is making a pledge to cut added sugars in Europe. The Union of European Soft Drinks Associations (UNESDA) announced on June 29 this year to reduce average added sugars in its beverages by another 10% across Europe by 2025.
In its further commitment to Europe, Sweegen has aligned the availability of its Reb M with commercializing the high-purity sweetener at its manufacturing facility in Europe. The facility is open in Europe for helping food and beverage manufacturers with rapid production and low cost-in-use sugar reduction solutions.
To compliment the approval of Reb M, Sweegen invested in designing and building its Innovation Studio in Reading, England, near London. The studio opened its doors in January 2021 with a full applications team to collaborate with food and beverage manufacturers on exploring the entire consumer landscape to understand what trends are driving consumer behavior, and then provide inspirational ingredients to represent those trend drivers.
“Our rapid innovation in application development enables our customer-focused solutions to help manufacturers create great-tasting, clean, natural, plant-based, sustainable products that meet today’s end-consumer needs and desires,” said Giannone.
Around the world, Sweegen’s Innovation Studios are open globally: Southern California, Mexico City, Reading (London) and very soon in Singapore. These studios will leverage local tastes and knowledge while serving as creative centers to explore and discover product innovations motivated by consumer trends and regional tastes.
“Sweegen’s global regulatory mission is the hallmark of opening new sugar reduction opportunities to manufacturers and brands for replacing sugar in foods and beverages, nutritional products, and many other market products world-wide,” said Hadi Omrani, director of regulatory affairs. “Europe is an important region in our global regulatory vision as we continually forge the future of wellness in food and drink around the world.”
Sweegen offers brands cost-effective and rapid innovation for sugar reduction solutions for beverage, dairy, savory and bakery with its Bestevia Taste Solutions for Europe.
Sweegen is the first company to receive the European Food Safety Authority (EFSA) panel’s safety status for any steviol glycoside produced by alternative and sustainable technologies. To achieve high purity clean-tasting stevia leaf sweeteners, Sweegen uses a bioconversion process starting with the stevia leaf. This process enabled Sweegen to obtain the Non-GMO Project verification for its Signature Bestevia stevia sweeteners in the U.S. market.
Bestevia Reb M was commercialized in 2017 and has already been approved in many regions around the world.
Sweegen provides sweet taste solutions for food and beverage manufacturers around the world.
We are on a mission to reduce the sugar and artificial sweeteners in our global diet. Partnering with customers, we create delicious zero-sugar products that consumers love. With the best Signature Stevia sweeteners in our portfolio such as Bestevia® Rebs B, D, E, I, M, and N, along with our deep knowledge of flavor modulators and texturants, Sweegen delivers market-leading solutions that customers want and consumers prefer.
For more information, please contact email@example.com and visit Sweegen’s website, www.sweegen.com.
Cautionary Statement Concerning Forward-Looking Statements
This press release contains forward-looking statements, including, among other statements, statements regarding the future prospects for Reb M stevia leaf sweetener. These statements are based on current expectations, but are subject to certain risks and uncertainties, many of which are difficult to predict and are beyond the control of Sweegen, Inc.
Relevant risks and uncertainties include those referenced in the historic filings of Sweegen, Inc. with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from those expressed in or implied by the forward-looking statements, and therefore should be carefully considered. Sweegen, Inc. assumes no obligation to update any forward-looking statements as a result of new information or future events or developments.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Leading Edge Materials Announces Filing of Preliminary Economic Assessment Report for Woxna Graphite Anode Project26.7.2021 14:30:00 CEST | Press release
Vancouver, July 26, 2021 – Leading Edge Materials Corp. (“Leading Edge Materials” or the “Company”) (TSXV: LEM) (Nasdaq First North: LEMSE) (OTCQB: LEMIF) is pleased to announce that the technical report for its Woxna Graphite project (the “Project”) titled “NI 43-101 Technical Report – Woxna Graphite” with effective date June 9, 2021, has been filed under the Company’s profile on SEDAR today (the “Report” or “PEA”). The Report supports the disclosure in the Company’s news release dated June 9, 2021. All figures in the Report are US dollars unless otherwise specified. The news release on June 9, 2021, presented these highlights of the Report: Main PEA Highlights The PEA indicates the potential viability of a Swedish operation producing battery grade graphite anode material utilizing an existing graphite mine and concentrator with the addition of a value-add processing facility offsite;The proposed process route in the PEA uses a thermal purification process which, combined with access
Cavotec wins key motorised cable reel order for advanced container cranes in Japan26.7.2021 09:00:00 CEST | Press release
Cavotec has won a key order for its innovative motorised cable reel systems for integration onto advanced rail-mounted gantry cranes at the Port of Tokyo – a project that highlights Cavotec’s position as a trusted supplier of mission-critical systems at ports and terminals. “Given the complexity of these high-end cranes and their demanding operational environment, this is an excellent reference for us as we continue to grow in Japan and the wider region,” says Robin Shang, Cavotec Regional Sales Director Ports & Maritime. Cavotec will supply motorised cable reel systems for eight automated rail-mounted gantry (ARMG) cranes at the Wan Hai Tokyo Oi5 terminal, a major global container handling hub. The cable reels will ensure the cranes meet demanding performance requirements due to surging container volumes. Working closely with Chin Pan engineering group, Cavotec is scheduled to complete the delivery of the systems in early 2023. Previously, Chin Pan has fitted two ARMGs cranes successf
Scandinavian Tobacco Group A/S: Transactions in connection with share buy-back programme26.7.2021 08:44:35 CEST | Press release
Company Announcement No. 38/2021 Copenhagen, 26 July 2021 Transactions in connection with share buy-back programme On 10 March 2021, Scandinavian Tobacco Group A/S (“STG”) announced that a share buy-back programme of an aggregated price of up to DKK 600 million was launched with the purpose to adjust the Company’s capital structure and meet obligations relating to the Group’s share-based incentive programme. The buy-back programme is executed in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (the “Market Abuse Regulation”) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. The share buy-back programme will end no later than 28 February 2022. The following transactions have been executed from 19 July to 23 July 2021: Number of sharesAverage purchase price, DKKTransaction value, DKKAccumulated, last announcement1,781,412222,947,59319 July 202120,000125.242,504,78020 July 202115,510125.551,947,26
Saniona Receives U.S. FDA Orphan Drug Designation for Tesomet in Hypothalamic Obesity26.7.2021 08:00:00 CEST | Press release
PRESS RELEASE July 26, 2021 Tesomet is the first and only investigational treatment for hypothalamic obesity to receive orphan drug designation Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Tesomet for the treatment of hypothalamic obesity (HO). Tesomet is the first and only investigational treatment for HO to receive orphan drug designation. Saniona is preparing to initiate two Phase 2b studiesof Tesomet in the second half of this year, one in HO and the other in Prader-Willi syndrome (PWS), for which Tesomet has already received orphan drug status. “There are currently no FDA-approved medicines for hypothalamic obesity. Despite the devastating weight gain and hunger this rare disease can cause, there has been relatively little drug development specifically for HO. Saniona is proud to be pioneering a regulatory path forward for people li
SERSTECH AB: Half-year report 1 January – 30 June 202126.7.2021 08:00:00 CEST | Press release
Serstech Group Second quarter 2021 Net sales: KSEK 2 765 (308)Profit for the period: KSEK -5 299 (-6 820)Earnings per share: SEK -0.06 (-0.10)Earnings per average number of shares: SEK -0.07 (-0.10) Serstech Group Period 1 January - 30 June 2021 Net sales: KSEK 14 224 (6 321)Profit for the period: KSEK -2 270 (-10 025)Earnings per share: SEK -0.03 (-0.14)Earnings per average number of shares: SEK-0.03 (-0.14) The second quarter brought a slight increase in orders received compared to the previous quarter, but we clearly see remaining effects of the pandemic in most parts of the world. We have not lost any tenders during the quarter, which is encouraging and again suggests that there is an unmet demand in the market. We do expect an increase in sales over the next six months, as the buyers become more active and the important demo sessions can be arranged safely again. Buyers in our industry will not buy an instrument they have not tested themselves and therefore they postpone procureme
Reminder of an Investor Conference Webinar26.7.2021 08:00:00 CEST | Press release
We would like to remind that KN invites shareholders, investors, analysts and other stakeholders to join its investor conference webinar scheduled on the July 29th of 2021 at 9.00 am (EET). The presentation will be held in English. The webinar will be hosted by KN Chief Executive Officer Darius Šilenskis and acting Chief Financial Officer Indrė Kisielienė who will introduce the performance and unaudited financial results of KN for the six months of 2021. How to join the webinar? To join the webinar, please register via following link: https://register.gotowebinar.com/register/6420133473151346701You will be provided with the webinar link and instructions how to join successfully. When joining the webinar for the first time, you will be asked to download the plug-in which will take only few seconds. In case plug-in can't be downloaded, a web browser which enables attending the webinar, opens automatically. The webinar will be recorded and available online for everyone at the company’s we
Van Lanschot Kempen’s partnership with Mercier Vanderlinden finalised26.7.2021 08:00:00 CEST | Press release
’s-Hertogenbosch/Amsterdam, the Netherlands, 26July2021 Van Lanschot Kempen and Mercier Vanderlinden today announced that they have completed the transaction that sees Van Lanschot Kempen acquire a 70% stake in Mercier Vanderlinden. The regulators have issued declarations of no objection, and Van Lanschot Kempen and Mercier Vanderlinden have thus joined forces in the Belgian wealth management market. Van Lanschot Kempen will increase step-by-step its 70% stake in Mercier Vanderlinden to 100%. Mercier Vanderlinden and Van Lanschot Kempen in Belgium will continue to operate independently and collaborate in a number of areas. The partners are a good fit in terms of client portfolios and networks, product offering and geographical coverage. Between them, they had €9.3 billion in client assets at 30 June 2021. In the past few years, both Van Lanschot Kempen in Belgium and Mercier Vanderlinden have achieved robust client asset growth, and they will continue their role as market challengers o